
Customize View

Include Strategic Alliances for:Current subsidiaries



Strategic Alliances

Recently Disclosed Strategic Alliances
There are no recently disclosed strategic alliances listed

Prior and Not Recently Disclosed Strategic Alliances
Strategic Alliance Name
Company Name
Primary Industry
Source
CNS Pharmaceuticals, Inc. (NasdaqCM:CNSP)
WPD Pharmaceuticals Inc. (CNSX:WBIO)
Pharmaceuticals
Key DevelopmentClient Announcements Apr-08-2020
Business Description: CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The companyâ€™s lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.
Full Metal Minerals Ltd. (OTCPK:FLMT.F)
Westcot Ventures Corp.
Diversified Metals and Mining
Full Metal Minerals Ltd. (OTCPK:FLMT.F) 2010 Form Doc
Business Description: Full Metal Minerals Ltd., an exploration stage company, engages in the acquisition, exploration, and development of mineral properties in Canada. It holds an option to acquire a 60% interest in the Olivine Mountain property located in the Similkameen Mining Division, British Columbia. The company was incorporated in 2003 and is headquartered in Vancouver, Canada.
*denotes proprietary relationship